Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Peripheral Arterial Disease: Features

Dr Tepe
ISET 2023
Reintervention Patterns Among Patients With In-Stent Restenosis, Long Lesions, and Chronic Total Occlusions
01/17/2023
On Tuesday, Gunnar Tepe, MD, from RoMed Hospital in Rosenheim, Germany, provided attendees with an update on reintervention patterns in patients with in-stent restenosis, long lesions, and chronic total occlusions.
On Tuesday, Gunnar Tepe, MD, from RoMed Hospital in Rosenheim, Germany, provided attendees with an update on reintervention patterns in patients with in-stent restenosis, long lesions, and chronic total occlusions.
On Tuesday, Gunnar Tepe, MD,...
01/17/2023
Vascular Disease Management
Dr Chandra
ISET 2023
12-Month Outcomes With a Paclitaxel DES: Highlighting the Impact of Vessel Sizing
01/17/2023
In a Tuesday ISET 2023 session, Venita Chandra, MD, from Stanford University in Stanford, California, presented study results on the use of paclitaxel with a drug-eluting stent (DES) and the importance of vessel sizing.
In a Tuesday ISET 2023 session, Venita Chandra, MD, from Stanford University in Stanford, California, presented study results on the use of paclitaxel with a drug-eluting stent (DES) and the importance of vessel sizing.
In a Tuesday ISET 2023 session,...
01/17/2023
Vascular Disease Management
Dr Beasley
ISET 2023
MIMICS-3D 3-Year Outcomes in Complex Lesions
01/17/2023
At Tuesday's ISET 2023 sessions, Dr. Robert Beasley presented 3-year results of MIMICS, a prospective, multicenter, observational study that evaluated BioMimics 3D in 507 patients with peripheral arterial disease at 23 investigational sites...
At Tuesday's ISET 2023 sessions, Dr. Robert Beasley presented 3-year results of MIMICS, a prospective, multicenter, observational study that evaluated BioMimics 3D in 507 patients with peripheral arterial disease at 23 investigational sites...
At Tuesday's ISET 2023 sessions,...
01/17/2023
Vascular Disease Management
Dr Schneider
ISET 2023
Intermediate-Term (24-Month) Results of the TRANSCEND Study: Comparing a Next-Generation Paclitaxel Drug-Coated Balloon (SurVeil DCB) to IN.PACT Admiral DCB in the Treatment of Femoropopliteal Artery Disease
01/17/2023
In this session from Tuesday afternoon, Peter A. Schneider, MD, Marianne Brodmann, MD, William Gray, MD, and Kenneth Rosenfield, MD reported 24-month results from the TRANSCEND study, which compared the SurVeil drug-coated balloon (DCB) to...
In this session from Tuesday afternoon, Peter A. Schneider, MD, Marianne Brodmann, MD, William Gray, MD, and Kenneth Rosenfield, MD reported 24-month results from the TRANSCEND study, which compared the SurVeil drug-coated balloon (DCB) to...
In this session from Tuesday...
01/17/2023
Vascular Disease Management
Dr Secemsky
ISET 2023
How IVUS Improves Clinical Outcomes
01/17/2023
In a Tuesday session at ISET, Dr. Eric Secemsky presented information on intravascular ultrasound imaging, which can significantly improve clinical outcomes in coronary interventions.
In a Tuesday session at ISET, Dr. Eric Secemsky presented information on intravascular ultrasound imaging, which can significantly improve clinical outcomes in coronary interventions.
In a Tuesday session at ISET,...
01/17/2023
Vascular Disease Management
Dr Secemsky
ISET 2023
Initial Study of New Device for Vessel Prep: BELONG Study 12-month Results
01/17/2023
Vessel preparation creates an optimal environment for primary therapy, such as angioplasty, drug-coated balloons, and stenting, according to Eric Secemsky, MD, Director of Vascular Intervention at Beth Israel Deaconess Medical Center in...
Vessel preparation creates an optimal environment for primary therapy, such as angioplasty, drug-coated balloons, and stenting, according to Eric Secemsky, MD, Director of Vascular Intervention at Beth Israel Deaconess Medical Center in...
Vessel preparation creates an...
01/17/2023
Vascular Disease Management
Dr Aronow
ISET 2023
Long-Term Follow-Up and Management of PAD
01/16/2023
During a Monday morning session, Dr. Herbert Aronow, president of the Society for Vascular Medicine, discussed long-term goals following endovascular therapy for PAD.
During a Monday morning session, Dr. Herbert Aronow, president of the Society for Vascular Medicine, discussed long-term goals following endovascular therapy for PAD.
During a Monday morning session,...
01/16/2023
Vascular Disease Management
Dr Simons
ISET 2023
Evaluation and Management of Intermittent Claudication and Chronic Limb Threatening Ischemia
01/16/2023
During Monday morning’s session on Essentials of Endovascular Therapy, Dr. Jessica P. Simons of UMass Chan Medical School presented information on evaluating and managing intermittent claudication and chronic limb-threatening ischemia (CLTI).
During Monday morning’s session on Essentials of Endovascular Therapy, Dr. Jessica P. Simons of UMass Chan Medical School presented information on evaluating and managing intermittent claudication and chronic limb-threatening ischemia (CLTI).
During Monday morning’s session...
01/16/2023
Vascular Disease Management
Editor's Corner
BEST-CLI Deep Dive II
12/15/2022
Dr. Walker continues his discussion of the BEST-CLI randomized control trial comparing surgery-first with or without an adequate venous conduit vs endovascular-first treatment in patients with CLTI.
Dr. Walker continues his discussion of the BEST-CLI randomized control trial comparing surgery-first with or without an adequate venous conduit vs endovascular-first treatment in patients with CLTI.
Dr. Walker continues his...
12/15/2022
Vascular Disease Management
Video
BEST-CLI: A Deeper Look
12/14/2022
Watch Dr. Matthew Finn continue his discussion on the BEST-CLI randomized trial.
Watch Dr. Matthew Finn continue his discussion on the BEST-CLI randomized trial.
Watch Dr. Matthew Finn continue...
12/14/2022
Vascular Disease Management

Advertisement

Advertisement

Stay in the Know

Vascular Disease Management Newsletter

Advertisement

Advertisement

News

First Aid guidelines
AHA/American Red Cross: Updated First Aid Guidelines Enhance Care for Opioid Overdose, Bleeding, Other Emergencies
11/14/2024
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major...
11/14/2024
Cath Lab Digest
Late-Breaking Trials
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/06/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a...
11/06/2024
Vascular Disease Management
Late-Breaking Trials
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/05/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/05/2024
Vascular Disease Management
Late-Breaking Trials
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Late-Breaking Trials
First Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Image-Guided Therapy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease
11/04/2024
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first...
11/04/2024
Vascular Disease Management
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
Peripheral Arterial Disease
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
11/04/2024
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November...
11/04/2024
Vascular Disease Management
Patient Awareness
Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases
10/31/2024
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in...
10/31/2024
Vascular Disease Management
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement